Physician profile
Tal Zivan
NPI 1639699796
$2,123.63
in general payments reported to CMS, 2019-2025
17 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.66 · 2021: $386 · 2022: $675 · 2023: $611 · 2024: $250 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $401.16 | 2023-2025 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $259.20 | 2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $228.91 | 2021-2022 | |
| Shockwave Medical, INC | $164.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $156.28 | 2021-2022 | |
| Abiomed | $139.95 | 2022-2023 | Impella |
| Abbott Laboratories | $131.65 | 2021 | |
| Aidoc Medical LTD | $131.00 | 2023 | Briefcase |
| Pfizer INC. | $125.90 | 2021-2024 | |
| Novo Nordisk INC | $103.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $73.18 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $50.21 | 2023-2024 | |
| Teleflex LLC | $49.52 | 2023 | Guideliner |
| Lantheus Medical Imaging, INC. | $35.02 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.35 | 2024-2025 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.56 | 2023 | |
| Philips North America LLC | $17.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tal Zivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.